The business of developing antibacterials

Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature biotechnology 2006-12, Vol.24 (12), p.1521-1528
1. Verfasser:	Fox, Jeffrey L
Format:	Artikel
Sprache:	eng
Schlagworte:	Agriculture Anti-Bacterial Agents - biosynthesis Anti-Bacterial Agents - immunology Antibacterial agents Antibiotics Antibody Specificity - immunology Backup software Bacterial Infections - immunology Bacterial Infections - prevention & control Bioinformatics Biological and medical sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Clinical Trials as Topic Commerce Daptomycin Drug Design Drug Industry - economics Drug Industry - trends Drug Resistance, Microbial feature Financing, Government Fundamental and applied biological sciences. Psychology Immunoglobulins, Intravenous - biosynthesis Immunoglobulins, Intravenous - therapeutic use Industrywide conditions Investments Legislation. General informations Life Sciences Methicillin Resistance - drug effects Methicillin Resistance - immunology Pharmaceutical industry Product development R&D Research & development Research Support as Topic Rifamycins Staphylococcus aureus - drug effects Staphylococcus aureus - immunology Startups Tetracyclines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.
ISSN:	1087-0156 1546-1696
DOI:	10.1038/nbt1206-1521